Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture ...

Discover key takeaways from Oracle's earnings results, why the stock nears buy territory, and insights on a cautious approach ...

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic ...

AISERA—A leading provider of generative AI solu- tions, Aisera helps enterprises boost revenue, improve user productivity, lower operating expenses, and create magical user experiences ... business ...

A bill that would generate new revenue for the state to address climate change and reduce the risk of future wildfires by ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on ...

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 ...

Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...

Conference Call and Webcast Today at 8:30 a.m. ETReached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical ...

A data leak unmasked a global network of alleged professional scammers drawing would-be investors into dodgy trading ...

the company implemented a series of measures in connection with moving to an outsourced analytical testing model and to reduce operating expenses. As a result, the company's cash runway was extended ...